AACR: ICMgp100 tolerated, active in advanced melanoma

AACR: ICMgp100 tolerated, active in advanced melanoma

(HealthDay)—An affinity-enhanced T cell receptor specific for the human leukocyte antigen-A2 restricted melanoma gp 100 peptide fused to an anti-CD3 antibody fragment, IMCgp100, seems promising for advanced melanoma, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 9 in San Diego.

Mark Middleton, M.D., Ph.D., from the NIHR Biomedical Research Centre in Oxford, U.K., and colleagues conducted a phase I study to determine the maximum tolerated dose and toxicity of ICMgp100. Thirty-one patients with were enrolled in eight cohorts and received doses of 5 to 900 ng/kg ICMgp100.

The researchers found that two of four patients developed grade 3 hypotension at a dose of 900 ng/kg, and consequently the maximum tolerated dose was established as 600 ng/kg. Transient grade 3 pruritic rash and grade 2 pyrexia were common toxicities. There was evidence of profound lymphocyte trafficking to the skin, as observed in immunohistochemical analysis of skin biopsies, and this was accompanied by chemokine/cytokine release. To date, four partial responses and multiple lesser responses have been documented, with one of the partial responses occurring after a single dose. Two partial responses persisted beyond more than nine months of continued treatment.

"The drug is well tolerated in advanced , and we have seen clinical responses in some of them," Middleton said in a statement.

The study was funded by Immunocore.

More information: Press Release
More Information

add to favorites email to friend print save as pdf

Related Stories

Chemo combination promising for multiple myeloma

May 02, 2012

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response ...

AACR: LY2835219 promising for metastatic breast cancer

Apr 07, 2014

(HealthDay)—The novel cell cycle inhibitor selective for the cyclin-dependent kinases CDK4 and CDK6 (CDK4/6), LY2835219, shows promise for metastatic breast cancer, according to a study presented at the ...

Recommended for you

Video: Is that double mastectomy really necessary?

2 hours ago

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments